Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.53 |
| ▸ | ITGAL | P20701 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255990 | 1.00 | P2RY14 (0.55) | P2RY14ALOX15ACEITGB2ICAM1 | |
| SCHEMBL20255508 | 0.95 | SHMT1 (0.57) | P2RY14ALOX15ACEITGB2ICAM1 | |
| SCHEMBL21560256 | 0.95 | SHMT1 (0.56) | P2RY14ALOX15ACEITGB2ICAM1 | |
| SCHEMBL20255789 | 0.95 | P2RY14 (0.61) | P2RY14ALOX15ACEITGB2ICAM1 | |
| SCHEMBL20255511 | 0.95 | SHMT1 (0.56) | P2RY14ALOX15ACEITGB2ICAM1 | |
| SCHEMBL20255602 | 0.93 | KMT2A (0.61) | P2RY14ACEITGB2ICAM1ITGAL | |
| SCHEMBL20255603 | 0.93 | POLB (0.63) | P2RY14ALOX15ACEPOLBSHMT1 | |
| SCHEMBL21560303 | 0.93 | ITGB2 (0.55) | P2RY14ACEITGB2ICAM1ITGAL | |
| SCHEMBL21560329 | 0.93 | ITGB2 (0.55) | P2RY14ACEITGB2ICAM1ITGAL | |
| SCHEMBL21560221 | 0.93 | ITGB2 (0.55) | P2RY14ALOX15ACEITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | P2RY14 4686/4885ALOX15 1598/4885ACE 2172/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | P2RY14 4686/4885ALOX15 1598/4885ACE 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.